Fintepla (fenfluramine) — Highmark
Dravet syndrome
Initial criteria
- age ≥ 2 years
- diagnosis of Dravet syndrome
- therapeutic failure, contraindication, or intolerance to two of the following: clobazam, topiramate, valproic acid or divalproex sodium
Reauthorization criteria
- prescriber attests that the member has experienced a reduction in seizure frequency from baseline
Approval duration
12 months